News

Free Art Classes for Patients, Caregivers Opening in Arkansas

Free art therapy workshops for Parkinson’s disease patients and their caregivers will take place this fall in Little Rock and Hot Springs, Arkansas, offered by the University of Arkansas for Medical Sciences (UAMS) Movement Disorders Clinic. The Art for Parkinson’s classes are scheduled in Little Rock at St. Michael’s…

Ventus, Novo Nordisk Partner on Anti-inflammatory Medications

Ventus Therapeutics and Novo Nordisk have agreed to work together to develop new anti-inflammatory medicines that may be useful in Parkinson’s disease and other disorders, the companies announced. “This is an important collaboration for Ventus that validates our structural biology capabilities to discover and develop highly differentiated…

Poor Sleep Raises Risk of Dyskinesia With Parkinson’s, Study Finds

Poor sleep quality is a key factor in developing dyskinesia, the uncontrolled and involuntary movements that can affect people with Parkinson’s disease, a study that followed patients for up to three years suggests. “[Poor sleep quality] may increase the risk of developing dyskinesia in PD [Parkinson’s disease], implying that therapeutic…

New Method Devised to Generate Dopaminergic Neurons

Researchers have devised a new method to generate dopamine-producing neurons from skin cells of Parkinson’s disease patients, a process that could be used to better study the molecular mechanisms of the disease and develop new treatments. The cells retained many relevant aspects of the disease, including the accumulation of…

Survival With Parkinson’s Tied to Age at Onset, Cognition in Study

Older age at onset, a faster rate of disease progression, and severe cognitive impairment are key factors in poorer survival rates for people with Parkinson’s disease, a study that followed patients in northern China for 10 years found. Fatigue may also be an indicator of poorer survival, while physical exercise…

GT-02287 Helps Prevent Toxic Alpha-synuclein in Patient-derived Cells

GT-02287, Gain Therapeutics’ experimental oral therapy, reduced the toxic alpha-synuclein protein clumps that characterize Parkinson’s disease in lab-grown nerve cells derived from patients with disease-causing mutations in the GBA1 gene, the company announced. The treatment also boosted the function of lysosomes, the cells’ recycling centers, which is…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums